Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04788043 · ClinicalTrials.gov registry record · Phase 2

Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma

A Phase 2 study of Hodgkin Lymphoma and Classic Hodgkin Lymphoma, sponsored by Stanford University.

Compiled by PlainTrial · August 8, 2026

Active
Registry status: Phase 2
Development phase: 8
Enrollment target: 2
Study locations

NCT04788043: Active Phase 2 study of Hodgkin Lymphoma and Classic Hodgkin Lymphoma, sponsored by Stanford University.

NCT04788043 is a Phase 2 study of Hodgkin Lymphoma and Classic Hodgkin Lymphoma that is active but no longer recruiting, run by Stanford University. The registered enrollment target is 8 participants, below the 166-participant average among 71 other Hodgkin Lymphoma trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04788043, a Phase 2 study of Hodgkin Lymphoma and Classic Hodgkin Lymphoma, is active but no longer recruiting, sponsored by Stanford University.

ACTIVE NOT RECRUITING
Registry status: Phase 2
Development phase: 8 participants
Enrollment target: 2
Study locations

Study Summary

The purpose of this study is to test the safety and efficacy of magrolimab in combination with pembrolizumab in patients with Hodgkin lymphoma.

Primary Outcome

Each participant's response to treatment will be assessed per the Lugano criteria. The criteria are: * Complete Response (CR): Complete disappearance of all lesions, evidence, and effects of disease * Partial Response (PR): ≥50% decrease in SPD of the 6 largest lesions with no increase in the size of the other nodes; splenic / hepatic nodules regress ≥50%, and with no new sites of disease * Stable disease (SD): less than PR. * Progressive disease (PD): sum of the product of dimensions (SPD) of

Conditions Studied

Hodgkin Lymphoma Classic Hodgkin Lymphoma Refractory Classic Hodgkin Lymphoma Relapsed Classical Hodgkin Lymphoma

Interventions

DRUG Pembrolizumab
PROCEDURE PET/CT
DRUG Magrolimab

Study Locations (2)

California

Stanford University - Stanford

Massachusetts

Dana Farber Cancer Institute - Boston

Trial Details

Field	Value
Enrollment Target	8 participants
Start Date	2022-06-21
Est. Completion	2027-10
Phase	Phase 2

Stanford University

1,744 total trials

What the registry record for NCT04788043 still lists

NCT04788043 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 166-participant average among 71 other Hodgkin Lymphoma trials with a reported enrollment target (95% lower).

The record links to 4 conditions, with Hodgkin Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.

NCT04788043 reports a single indexed study location in California, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT04788043 about?

NCT04788043 is a clinical study titled "Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma". The purpose of this study is to test the safety and efficacy of magrolimab in combination with pembrolizumab in patients with Hodgkin lymphoma.

What is the current status of trial NCT04788043?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2022-06-21. Estimated completion is 2027-10.

What conditions does trial NCT04788043 study?

This clinical trial studies the following conditions: Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma, Relapsed Classical Hodgkin Lymphoma.

What interventions are being tested in trial NCT04788043?

The interventions under investigation include: Pembrolizumab (DRUG), PET/CT (PROCEDURE), Magrolimab (DRUG).

Who is sponsoring clinical trial NCT04788043?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04788043 being conducted?

This trial has 2 study locations across California, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hodgkin Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04788043's enrollment target sits among peer trials

8 70th of 71 higher than 1 of 71 other Hodgkin Lymphoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hodgkin Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04788043, the US trial registry maintained by the National Library of Medicine. NCT04788043 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.